SAN DIEGO–(BUSINESS WIRE)–DTx Pharma, Inc. (DTx), a privately-held biotechnology company creating novel RNA-based therapeutics to treat the genetic drivers of disease, announced today that Arthur T. Suckow, Ph.D., Chief Executive Officer, and Denise Bevers, Chief Operating Officer, will participate in two upcoming virtual investor conferences.
Dr. Suckow and Ms. Bevers will both attend virtual one-on-one meetings at the 2021 Jefferies Virtual Healthcare Conference on June 2, 2021. Additionally, Dr. Suckow will present a company overview during the conference at 4: 30 PM EST on June 3, 2021.
Both executives will also attend virtual one-on-one meetings at the Evercore ISI GenomeRX Emerging Therapeutic Company Day on June 3, 2021.
About DTx Pharma
DTx Pharma, Inc. is a privately-held biotechnology company based in San Diego, CA creating novel RNA-based therapeutics to treat the genetic drivers of disease. The company’s proprietary delivery technology platform utilizes fatty acids as targeting ligands to enable the delivery of oligonucleotide therapies to tissues and cell types throughout the body. In preclinical studies, DTx has demonstrated cellular uptake and broad activity of oligonucleotides in the retina, muscle, heart, neurons, T cells, and other specialized cell types. To advance the FALCON platform toward and into clinical development, DTx has raised more than $100M in combined investment from several of the world’s leading healthcare investors including RA Capital Management and Access Biotechnology, pharmaceutical companies such as Eli Lilly and Company, the National Institute of Health (NIH), and research foundations such as the CMT Research Foundation (CMTRF). To learn more about DTx Pharma, please visit www.dtxpharma.com and follow DTx on LinkedIn and Twitter @DTxPharma.